No Data
Huadong Medicine Subsidiary Gets Aproval for HDM1005 Weight Management Drug Clinical Trials
Here's Why Huadong Medicine (SZSE:000963) Can Manage Its Debt Responsibly
Huadong Medicine (000963.SZ): The HDM1005 injection from Sino-American Huadong has been approved for clinical trials.
On January 2, Gelonghui reported that Huadong Medicine (000963.SZ) announced that on December 31, 2024, its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhongmei Huadong") received the "Clinical Trial Approval Notification" issued by the National Medical Products Administration (NMPA) (notification numbers: 2024LP03036 and 2024LP03037). The clinical trial application for HDM1005 injection submitted by Zhongmei Huadong has been approved. HDM1005 injection is developed and owned by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Huadong Medicine (000963.SZ): The application for listing permission of the exclusively distributed product, injectable ASSETREORGANIZATIONA botulinum toxin, has been accepted.
Huadong Medicine (000963.SZ) released an announcement, stating that on December 31, 2024, the company will exclusively distribute products related to...
Huadong Medicine (000963.SZ): The clinical trial application for the HDM1005 injection Pharmaceutical by Sino-American Huadong has received approval from the FDA in the USA.
On December 18, GELONGHUI reported that Huadong Medicine (000963.SZ) announced that on December 17, 2024, its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhongmei Huadong"), received notification from the FDA (the US Food and Drug Administration) that the clinical trial application for the HDM1005 injection, filed by Zhongmei Huadong, has been approved by the FDA, allowing Phase I clinical trials to be conducted in the USA. The HDM1005 injection is a long-acting agonist targeting both human GLP-1 and GIP receptors in the peptide category, a GLP-1 product.
Huadong Medicine (000963.SZ): Currently, there are no investments in AI pharmaceutical companies.
Gelonghui reported on December 16th that Huadong Medicine (000963.SZ) stated on the investor interaction platform that the company currently does not invest in AI pharmaceutical companies, but has established an AI-assisted drug development (AIDD) platform. Currently, this business has a small overall impact on the company.
Fewer Investors Than Expected Jumping On Huadong Medicine Co., Ltd (SZSE:000963)
